Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1998 Oct;74(876):587–591. doi: 10.1136/pgmj.74.876.587

Platelets, aspirin, and cardiovascular disease.

P C Elwood 1, C Hughes 1, J R O'Brien 1
PMCID: PMC2361007  PMID: 10211350

Abstract

Aspirin was first synthesised 100 years ago and its preparation and marketing is generally reckoned to have been the foundation of the pharmaceutical industry. For most of the time since then it has been used for the relief of pain and fever. The modern phase of aspirin use commenced with the reporting in 1974 of a randomised controlled trial in the secondary prevention of death by low-dose aspirin given to patients who had suffered a myocardial infarct. Reports of other trials followed and an overview of the first six trials was presented to the inaugural meeting of the Society for Clinical Trials in Philadelphia in 1980. There have been two further major overviews and the most recent, based on 145 trials, established that low-dose aspirin reduces vascular events by around one third. It has been estimated that, used appropriately, aspirin could prevent 100,000 premature deaths each year worldwide, at a cost of about 250 Pounds ($400) per life saved, and about 80 Pounds ($130) per cardiovascular event prevented. The evidence indicates that it is seriously underused at present. The aspirin story continues and trials are in progress to test other possible uses of aspirin, in vascular dementia, colorectal cancer, and cataract.

Full text

PDF
591

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BORN G. V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962 Jun 9;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  2. Breddin K., Loew D., Lechner K., Uberla K., Walter E. Secondary prevention of myocardial infarction: a comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis. 1980;9(6):325–344. doi: 10.1159/000214375. [DOI] [PubMed] [Google Scholar]
  3. CRAVEN L. L. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg. 1950 Feb;4(2):95–95. [PubMed] [Google Scholar]
  4. CRAVEN L. L. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956 Sep;78(5):213–215. [PubMed] [Google Scholar]
  5. Elwood P. C., Cochrane A. L., Burr M. L., Sweetnam P. M., Williams G., Welsby E., Hughes S. J., Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974 Mar 9;1(5905):436–440. doi: 10.1136/bmj.1.5905.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Elwood P. C., Sweetnam P. M. Aspirin and secondary mortality after myocardial infarction. Lancet. 1979 Dec 22;2(8156-8157):1313–1315. doi: 10.1016/s0140-6736(79)92808-3. [DOI] [PubMed] [Google Scholar]
  7. FRICK P. G. Hemorrhagic diathesis with increased capillary fragility caused by salicylate therapy. Am J Med Sci. 1956 Apr;231(4):402–406. doi: 10.1097/00000441-195604000-00005. [DOI] [PubMed] [Google Scholar]
  8. Greenberg E. R., Baron J. A., Freeman D. H., Jr, Mandel J. S., Haile R. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993 Jun 2;85(11):912–916. doi: 10.1093/jnci/85.11.912. [DOI] [PubMed] [Google Scholar]
  9. Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet. 1992 Sep 12;340(8820):645–648. doi: 10.1016/0140-6736(92)92177-h. [DOI] [PubMed] [Google Scholar]
  10. Kähler C. M., Kieselbach G. F., Reinisch N., Troger J., Göttinger W., Wiedermann C. J. Fibroblast growth-promoting activity in proliferative vitreoretinopathy: antagonism by acetylsalicylic acid. Eur J Pharmacol. 1994 Sep 12;262(3):261–269. doi: 10.1016/0014-2999(94)90740-4. [DOI] [PubMed] [Google Scholar]
  11. McCallum A. K., Whincup P. H., Morris R. W., Thomson A., Walker M., Ebrahim S. Aspirin use in middle-aged men with cardiovascular disease: are opportunities being missed? Br J Gen Pract. 1997 Jul;47(420):417–421. [PMC free article] [PubMed] [Google Scholar]
  12. Meyer J. S., Rogers R. L., McClintic K., Mortel K. F., Lotfi J. Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc. 1989 Jun;37(6):549–555. doi: 10.1111/j.1532-5415.1989.tb05688.x. [DOI] [PubMed] [Google Scholar]
  13. O'BRIEN J. R. THE MECHANISM AND PREVENTION OF PLATELET ADHESION AND AGGREGATION CONSIDERED IN RELATION TO ARTERIAL THROMBOSIS. Blood. 1964 Sep;24:309–314. [PubMed] [Google Scholar]
  14. O'BRIEN J. R. The adhesiveness of native platelets and its prevention. J Clin Pathol. 1961 Mar;14:140–149. doi: 10.1136/jcp.14.2.140. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. O'Brien J. R. Effects of salicylates on human platelets. Lancet. 1968 Apr 13;1(7546):779–783. doi: 10.1016/s0140-6736(68)92228-9. [DOI] [PubMed] [Google Scholar]
  16. O'Brien J. R., Tulevski V., Etherington M. Two in-vivo studies comparing high and low aspirin dosage. Lancet. 1971 Feb 20;1(7695):399–400. doi: 10.1016/s0140-6736(71)92237-9. [DOI] [PubMed] [Google Scholar]
  17. O'brien J. R. Platelet aggregation: Part I Some effects of the adenosine phosphates, thrombin, and cocaine upon platelet adhesiveness. J Clin Pathol. 1962 Sep;15(5):446–452. doi: 10.1136/jcp.15.5.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Richards M., Meade T. W., Peart S., Brennan P. J., Mann A. H. Is there any evidence for a protective effect of antithrombotic medication on cognitive function in men at risk of cardiovascular disease? Some preliminary findings. J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):269–272. doi: 10.1136/jnnp.62.3.269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Shiff S. J., Koutsos M. I., Qiao L., Rigas B. Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res. 1996 Jan 10;222(1):179–188. doi: 10.1006/excr.1996.0023. [DOI] [PubMed] [Google Scholar]
  20. Stuart R. K. Platelet function studies in human beings receiving 300 mg. of aspirin per day. J Lab Clin Med. 1970 Mar;75(3):463–471. [PubMed] [Google Scholar]
  21. Thun M. J., Namboodiri M. M., Heath C. W., Jr Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991 Dec 5;325(23):1593–1596. doi: 10.1056/NEJM199112053252301. [DOI] [PubMed] [Google Scholar]
  22. Vogel R. A. Aspirin and coronary disease. N Engl J Med. 1996 Oct 10;335(15):1161–1162. doi: 10.1056/NEJM199610103351517. [DOI] [PubMed] [Google Scholar]
  23. Weiss H. J., Aledort L. M. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet. 1967 Sep 2;2(7514):495–497. doi: 10.1016/s0140-6736(67)91658-3. [DOI] [PubMed] [Google Scholar]
  24. Weiss H. J., Aledort L. M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep;47(9):2169–2180. doi: 10.1172/JCI105903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Wijnja L., Snijder J. A., Nieweg H. O. Acetylsalicylic acid as a cause of pancytopenia from bone-marrow damage. Lancet. 1966 Oct 8;2(7467):768–770. doi: 10.1016/s0140-6736(66)90363-1. [DOI] [PubMed] [Google Scholar]
  26. Zucker M. B., Peterson J. Inhibition of adenosine diphosphate-induced secondary aggregation and other platelet functions by acetylsalicylic acid ingestion. Proc Soc Exp Biol Med. 1968 Feb;127(2):547–551. doi: 10.3181/00379727-127-32737. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES